Obstacles to the Adoption of Biosimilars for Chronic Diseases

This Viewpoint explores why biosimilars for chronic diseases, the largest category of biological therapies, are unlikely to yield cost savings.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qpBkDu
via IFTTT